AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

CorA human medicine

Summary

Corallopyronin A is a new antibiotic in filarial and dirofilarial infections with a new mode of action resulting in fewer adverse reaction and unlikelyness of resistances development.

Technology Benefits

Effective control of dirofilarial infections
Kills larvae as well as adult worms
Requires fewer treatment cycles in logistically difficult regions
Treatment of children is probable
Oral administration is possible
Alternative mode of action avoids selection for rifampicin cross-resistant M. tuberculosis

Technology Application

The current treatment approach targets the worm itself. The drugs, e.g. diethylcarbamazine and ivermectin, mainly kill larvae.

Detailed Technology Description

Corallopyronin A (CorA) has efficacy against the intracellular Wolbachia of filarial nematodes. Experiments in mice show that all worms were depleted of more than 98% of their Wolbachia, resulting in blocked larval development and phenotypically altered worms. The results indicate the potential of CorA to effectively eliminate filarial disease by killing larvae as well as adult worms with one (maximum of two) treatment regimens.

Type of Cooperation

Licensing

Application Date

04/05/2012 00:00:00

Application No.

EP20120721456 20120504

Classes

- international:
A61K31/366; A61P31/04; A61P33/00
- cooperative:
A61K31/366; C07D309/38; Y02A50/421; Y02A50/422

Others

Patent application

ID No.

2838

Country/Region

Germany

For more information, please click Here